ArticleJournal of diabetes research2026
Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross-Sectional and Sex-Stratified Analyses.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 'Family Violence and Football' at 15: Revisiting the Effect of Emotional Cues on Intimate Partner Violence.International journal of environmental research and public health · 2026Article
- Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross-Sectional and Sex-Stratified Analyses.Journal of diabetes research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sarcopenia is prevalent in Type 2 diabetes mellitus (T2DM). Whether thyroid-related hormones within the euthyroid range can help identify sarcopenia risk remains unclear. This study was aimed at evaluating the association of euthyroid-range thyroid markers with sarcopenia and their utility in risk stratification among adults with T2DM. Methods: We analyzed 1823 adults with T2DM (2019-2023). Sarcopenia was defined per Asian Working Group for Sarcopenia 2019 criteria. Muscle mass was assessed via multifrequency bioelectrical impedance analysis, handgrip strength via dynamometer, and gait speed via 6-m walk test. Multivariate linear and logistic models were adjusted for demographics, diabetes duration, body mass index, nephropathy, glycated hemoglobin, and antidiabetic medications. Discriminatory ability was evaluated using receiver operating characteristic curves, change in the area under the receiver operating characteristic curve ( Results: Higher free triiodothyronine (FT3) levels correlated with greater muscle mass, handgrip strength, and gait speed. Among thyroid markers, FT3 showed the strongest discrimination for sarcopenia (AUROC = 0.633). The optimal cutoff was 3.62 pmol/L (sensitivity, 85.6% and specificity, 35.7%), although overall performance was modest. Low FT3 independently predicted sarcopenia (odds ratio [OR], 2.26; Conclusion: FT3 provides modest but superior discrimination than thyroxine or thyroid-stimulating hormone and may support early sarcopenia risk detection in T2DM, particularly at low levels, with a possible sex-specific pattern but no significant interaction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.